The TJX Companies, inc. TJX
Yesterday we noted that TJX was exhibiting some interesting premarket activity despite missing EPS estimates on its Q4 earnings call. We also mentioned that we’d look for the very common dip-and-rip scenario, which occurred on cue.
Our options targets were the TJX 03/16 $80-85 Calls, and unsurprisingly, we got considerable gain opportunities out of all three sets of contracts in that range:
$80 Calls – Range: 3.30-5.10 – Max Gain: 55%
$82.50 Calls – Range: 1.70-3.00 – Max Gain: 76%
$85 Calls – Range: .75-1.56 – Max Gain: 93%
Endocyte, Inc. ECYT
Yesterday morning, we took the initiative to tag ECYT in our premarket report for the first time since November. The stock had already been steadily rising for a few weeks despite the reporting of Q4 losses, and the company revealed the pricing of a public offering at 4.20/share.
That helped to bring the biggest single session upswing for the stock since October, with ECYT running from a low of 4.51 up to 6.08. It was good for a highly respectable 35% increase, and sufficient to have the stock claim the title of top NASDAQ gainer of the day.
MARA, FCEL HIIQ, DDD, NVCM, NWL, AKRX